Showing results (531-540 of 14,087) with videos related to

Sort By:
Pageof 1,409
Gynecologic Oncology|November 1, 1992
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group studyW J Hoskins, B N Bundy, J T Thigpen, et al.
Gynecologic Oncology|November 1, 1992
Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancerL G Sandles, L P Shulman, S Elias, et al.
Gynecologic Oncology|November 1, 1992
Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitroM Untch, B U Sevin, J P Perras, et al.
Gynecologic Oncology|November 1, 1992
Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assayR D Hightower, B U Sevin, J P Perras, et al.
Gynecologic Oncology|September 24, 2004
Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomiesChristhardt Köhler, Petra Klemm, Anja Schau, et al.
Gynecologic Oncology|September 24, 2004
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancersMaurie Markman, Kenneth Webster, Kristine Zanotti, et al.
Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.
Gynecologic Oncology|September 24, 2004
Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature reviewPedro T Ramirez, Michael Frumovitz, Diane C Bodurka, et al.
Gynecologic Oncology|September 24, 2004
Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancersToru Hachisuga, Toshiaki Saito, Junzo Kigawa, et al.
Gynecologic Oncology|September 24, 2004
Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancerD Scott McMeekin, Todd Tillmanns, Taimur Chaudry, et al.
Pageof 1,409